Save the date next month and RP

Posted:
26
August 2010

Save the date next month and RPL will see you for the American College of Clinical Pharmacologys (ACCP) 39th Annual Meeting taking place 12th to 14th September 2010 in Baltimore, Maryland.

The Annual Meeting will cover a wide array of topics such as international drug development and collaboration, pharmacometrics, pharmacogenomics, and specific sessions relating to biologics, nutraceuticals, and drug therapy in special populations, providing an ideal platform for scientists of various disciplines to meet and discuss areas of common interest.

We invite you to come down and see us at our booth that will be located in Harborside DE zone at the Baltimore Marriott Waterfront Hotel. In addition we are pleased to announce that Dr Jorg Taubel, MD., FFPM., Clinical Pharmacologist and Principal Investigator at Richmond Pharmacology, is due to present at the Annual Meeting where he will address two core topics of discussion, namely:

  • 132 - Repeated Dosing of Strontium Ranelate 4G Over 15 days Does Not Prolong QTC Interval in Healthy Volunteers
  • 133 - PET500 A Newly Formulated Tetracaine Product is Effective in Reducing Penile Sensitivity  

Dr Taubel�s presentation has been scheduled for Poster Session 2 on Monday, 13th September, 2010 from 6 PM � 7:30 PM and there are also a number of other learning activities in store, so be sure not to miss out on what is expected to be both an educational and rewarding conference.

For more information on the Annual Meeting click here for further details or click here to view the preliminary meeting program.

We look forward to seeing you next month in Baltimore!

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more